General Information of Drug Therapeutic Target (DTT) (ID: TT3JF7X)

DTT Name HUMAN interleukin 8 (IL8)
Synonyms
T-cell chemotactic factor; Protein 3-10C; Neutrophil-activating protein 1; NAP-1; Monocyte-derived neutrophil-activating peptide; Monocyte-derived neutrophil chemotactic factor; MONAP; MDNCF; IL8; IL-8; Granulocyte chemotactic protein 1; GCP-1; Emoctakin; Chemokine (C-X-C motif) ligand 8; C-X-C motif chemokine 8
Gene Name CXCL8
BioChemical Class
Cytokine: interleukin
UniProt ID
IL8_HUMAN
TTD ID
T90070
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MTSKLAVALLAAFLISAALCEGAVLPRSAKELRCQCIKTYSKPFHPKFIKELRVIESGPH
CANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS
Function
IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.
KEGG Pathway
Cytokine-cytokine receptor interaction (hsa04060 )
Viral protein interaction with cytokine and cytokine receptor (hsa04061 )
Chemokine signaling pathway (hsa04062 )
NF-kappa B signaling pathway (hsa04064 )
Phospholipase D signaling pathway (hsa04072 )
Cellular senescence (hsa04218 )
Toll-like receptor signaling pathway (hsa04620 )
NOD-like receptor signaling pathway (hsa04621 )
RIG-I-like receptor signaling pathway (hsa04622 )
IL-17 signaling pathway (hsa04657 )
Non-alcoholic fatty liver disease (hsa04932 )
AGE-RAGE signaling pathway in diabetic complications (hsa04933 )
Alcoholic liver disease (hsa04936 )
Epithelial cell signaling in Helicobacter pylori infection (hsa05120 )
Pathogenic Escherichia coli infection (hsa05130 )
Shigellosis (hsa05131 )
Salmonella infection (hsa05132 )
Pertussis (hsa05133 )
Legionellosis (hsa05134 )
Yersinia infection (hsa05135 )
Chagas disease (hsa05142 )
Malaria (hsa05144 )
Amoebiasis (hsa05146 )
Hepatitis B (hsa05161 )
Human cytomegalovirus infection (hsa05163 )
Influenza A (hsa05164 )
Kaposi sarcoma-associated herpesvirus infection (hsa05167 )
Coronavirus disease - COVID-19 (hsa05171 )
Pathways in cancer (hsa05200 )
Transcriptional misregulation in cancer (hsa05202 )
Bladder cancer (hsa05219 )
Rheumatoid arthritis (hsa05323 )
Lipid and atherosclerosis (hsa05417 )
Reactome Pathway
Peptide ligand-binding receptors (R-HSA-375276 )
Chemokine receptors bind chemokines (R-HSA-380108 )
ATF4 activates genes in response to endoplasmic reticulum stress (R-HSA-380994 )
G alpha (i) signalling events (R-HSA-418594 )
Interleukin-10 signaling (R-HSA-6783783 )
Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807 )
Senescence-Associated Secretory Phenotype (SASP) (R-HSA-2559582 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-986253 DM42B0C Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health.